Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment With Recombinant Human Insulin-like Growth Factor 1 (rhIGF-1) in Patients With Pappalysin-2 (PAPP-A2) Gene Mutation.

NCT02636270 is registered in ClinicalTrials.gov with Children's Hospital Medical Center, Cincinnati as lead sponsor.

NCT NCT02636270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02636270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment With Recombinant Human Insulin-like Growth Factor 1 (rhIGF-1) in Patients With Pappalysin-2 (PAPP-A2) Gene Mutation.
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Phase
Phase 1/2
Overall status
Completed
Start date
December 21, 2015
Completion date
December 1, 2022
Enrollment
7 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

short stature